Cdc42 in osterix-expressing cells alters osteoblast behavior and myeloid lineage commitment

Area of Science:

• Bone Biology
• Hematopoiesis
• Cell Signaling

Background:

• Osteoblasts are key regulators of bone formation and also support hematopoiesis.
• Rho GTPases, including Cdc42, are involved in osteoblast signaling pathways.
• The precise role of Cdc42 in osteoblast function and its impact on hematopoiesis require further elucidation.

Purpose of the Study:

• To investigate the role of Cdc42 in osteoblast function and bone mineral density.
• To determine the effect of Cdc42 deletion in osteoblasts on hematopoiesis.
• To explore the underlying mechanisms by which Cdc42 influences bone and blood cell development.

Main Methods:

• Utilized transgenic mouse models with targeted Cdc42 deletion using Osterix and Collagen-α1(I) promoters.
• Administered Cdc42 inhibitors in vitro to assess cellular responses.
• Evaluated bone mineral density, osteoblast numbers, and hematopoietic stem and progenitor cells (HSPCs).
• Confirmed causality through in vitro experiments and assessed the role of interleukin-4.

Main Results:

• Deletion of Cdc42 in vivo suppressed osteoblast function and decreased bone mineral density.
• Targeted deletion using the Collagen-α1(I) promoter reduced osteoblast numbers.
• Cdc42 deletion using the Osterix promoter increased common myeloid progenitors (CMPs), erythrocytes, and platelets.
• In vitro studies confirmed causality and implicated interleukin-4 in mediating increased myelopoiesis.

Conclusions:

• Cdc42 is essential for maintaining bone health by regulating osteoblast function and number.
• Cdc42 expression in early osteoblasts/stromal cells is critical for modulating myelopoiesis.
• Osteoblasts play a significant role in regulating hematopoiesis, with Cdc42 being a key mediator.